ACT NOW

DONT LET RETAINED BLOOD SYNDROME BLOCK YOUR PATIENTS RECOVERY

Improve Outcomes, Lower Costs

Learn more about the innovative new

technology of PleuraFlow Active
Clearance Technology (ACT).

info@clearflow.com
www.clearflow.com

FLOW BETTER
Ordering Information
CODE

DESCRIPTION

PF-20

20FR PleuraFlow ACT System*

PF-24

24FR PleuraFlow ACT System*

PF-28

28FR PleuraFlow ACT System*

PF-32

32FR PleuraFlow ACT System*

Contact your local representative:

*PleuraFlow ACT System includes a straight silicone chest tube

and clearance apparatus.

Copyright 2014 ClearFlow, Inc. All Rights Reserved.

References

Trademarks and Registered Trademarks of ClearFlow, Inc.

US Patents 7,854,728, 7,951,243, 8,048,233, 8,246,752, 8,388,759,
8,702,662, and 8,951,355. International Patents AU 2004235782;
CA 2,565,303. Other US and international patents pending.

1 Karimov, J.H., Gillinov, A.M., Schenck, L., et al. Incidence of chest tube clogging after cardiac surgery:
a single-centre prospective observational study. Eur J Cardiothorac Surg. 2013;44(6):1029-1036.
doi:10.1093/ejcts/ezt140.

US FDA 510(k): K093565; Health Canada License Number 82994;

ARTG Identifier 218317

Manufactured For:

EU Authorized Representative:

ClearFlow, Inc.
1630 S. Sunkist St., Suite E
Anaheim, CA, US, 92806

Emergo Europe
Molenstraat 15
2513 BH, The Hague
The Netherlands

ML004-I
MCV00031391 REVA

2 Shiose, A., Takaseya, T., Fumoto, H., et al. Improved drainage with active chest tube clearance.
Interact CardioVasc Thorac Surg. 2010;10:685-688. doi: 10.1510/icvts.2009.229393.
3 Dixon, B., Santamaria, J.D., Reid, D., et al. The association of blood transfusion with mortality after
cardiac surgery: cause or confounding? Transfusion. 2013;53(1):19-27. doi:
10.1111/j.1537-2995.2012.03697.x.
4 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality
(AHRQ) Healthcare Cost and Utilization Project (HCUP). Data extracted using ICD-9 codes from over
313,000 US adult heart surgery patients. Analysis performed by Fletcher Spaght, Inc.
5 Arakawa, Y., Shiose, A., Takaseya, T. et al. Superior Chest Drainage With an Active Tube Clearance
System: Evaluation of a Downsized Chest Tube. Ann Thorac Surg. 2011;91:580-583. doi:
10.1016/j.athoracsur.2010.10.018.

WITH PLEURAFLOW ACTIVE CLEARANCE TECHNOLOGY

BLOCKED TUBES
LEAD TO
COMPLICATIONS

KEEP CHEST
TUBES CLEAR
with PleuraFlow Active Clearance Technology (ACT)
Developed by cardiac surgeons, PleuraFlow ACT is a unique system that
proactively clears chest tubes and prevents the retention of blood in
the chest cavity. ACT technology is used to maintain tube patency and
clears the pathway to a successful recovery before and after discharge.

More than 36% of

patients suffer from
blocked chest tubes.

A recent prospective study found that of these failures,

86% are intra-thoracic and invisible to bedside caregivers1.
The crucial hours post-surgery, when the patient is still
bleeding, are vitally important. Why risk patient outcomes
on a conventional chest tube to evacuate blood from the
surgical site?

Blocked chest
tubes can lead to
Retained Blood
Syndrome in
your patients.

Retained Blood Syndrome (RBS) causes multiple

mechanical and inflammatory complications that may lead
to additional interventions and readmissions. 2,3

Complications Requiring Intervention*

ACUTE

SUB-ACUTE

CHRONIC

3-6%

9-12%

2-3%

pericardial tamponade,
hemothorax

bloody pleural (9-12%) and

pericardial (2%) effusions

constrictive pericarditis,
fibrothorax

hours

weeks

years

days

months

Clearance Loop enables

proactive clearance of
thrombus obstruction from
the chest tube and provides
real-time patency feedback.

16-23% combined
*References available upon request.

Patient outcomes
and healthcare costs
are seriously
impacted by RBS.

Unreimbursable Costs Per Patient with RBS4

COST OF CARE

LENGTH OF STAY

MORTALITY RATE

$28,814

5.8 days

doubled

per RBS

Increase

3% to 6%

55%

INCREASE

2x

Improve Patient
Safety

Minimize Patient
Discomfort

Reduce Hospital
Costs

By eliminating accumulated blood and

Our 20FR PleuraFlow removes nearly triple

The average cost to treat a patient

fluid at the surgical site, you reduce

the amount of blood than a traditional

with one or more RBS complications

risky and unwanted complications.

32FR drain 5 (525 ml vs. 183 ml) and your

that require a re-operation or

Plus, you will never again have to break

patients will benefit from a smaller and

intervention is $28,814. 4

sterility in order to clear a clogged tube.

more flexible silicone tube.

BLOCKED TUBES
LEAD TO
COMPLICATIONS

KEEP CHEST
TUBES CLEAR
with PleuraFlow Active Clearance Technology (ACT)
Developed by cardiac surgeons, PleuraFlow ACT is a unique system that
proactively clears chest tubes and prevents the retention of blood in
the chest cavity. ACT technology is used to maintain tube patency and
clears the pathway to a successful recovery before and after discharge.

More than 36% of

patients suffer from
blocked chest tubes.

A recent prospective study found that of these failures,

86% are intra-thoracic and invisible to bedside caregivers1.
The crucial hours post-surgery, when the patient is still
bleeding, are vitally important. Why risk patient outcomes
on a conventional chest tube to evacuate blood from the
surgical site?

Blocked chest
tubes can lead to
Retained Blood
Syndrome in
your patients.

Retained Blood Syndrome (RBS) causes multiple

mechanical and inflammatory complications that may lead
to additional interventions and readmissions. 2,3

Complications Requiring Intervention*

ACUTE

SUB-ACUTE

CHRONIC

3-6%

9-12%

2-3%

pericardial tamponade,
hemothorax

bloody pleural (9-12%) and

pericardial (2%) effusions

constrictive pericarditis,
fibrothorax

hours

weeks

years

days

months

Clearance Loop enables

proactive clearance of
thrombus obstruction from
the chest tube and provides
real-time patency feedback.

16-23% combined
*References available upon request.

Patient outcomes
and healthcare costs
are seriously
impacted by RBS.

Unreimbursable Costs Per Patient with RBS4

COST OF CARE

LENGTH OF STAY

MORTALITY RATE

$28,814

5.8 days

doubled

per RBS

Increase

3% to 6%

55%

INCREASE

2x

Improve Patient
Safety

Minimize Patient
Discomfort

Reduce Hospital
Costs

By eliminating accumulated blood and

Our 20FR PleuraFlow removes nearly triple

The average cost to treat a patient

fluid at the surgical site, you reduce

the amount of blood than a traditional

with one or more RBS complications

risky and unwanted complications.

32FR drain 5 (525 ml vs. 183 ml) and your

that require a re-operation or

Plus, you will never again have to break

patients will benefit from a smaller and

intervention is $28,814. 4

sterility in order to clear a clogged tube.

more flexible silicone tube.

ACT NOW

DONT LET RETAINED BLOOD SYNDROME BLOCK YOUR PATIENTS RECOVERY

Improve Outcomes, Lower Costs

Learn more about the innovative new

technology of PleuraFlow Active
Clearance Technology (ACT).

info@clearflow.com
www.clearflow.com

FLOW BETTER
Ordering Information
CODE

DESCRIPTION

PF-20

20FR PleuraFlow ACT System*

PF-24

24FR PleuraFlow ACT System*

PF-28

28FR PleuraFlow ACT System*

PF-32

32FR PleuraFlow ACT System*

Contact your local representative:

*PleuraFlow ACT System includes a straight silicone chest tube

and clearance apparatus.

Copyright 2014 ClearFlow, Inc. All Rights Reserved.

References

Trademarks and Registered Trademarks of ClearFlow, Inc.

US Patents 7,854,728, 7,951,243, 8,048,233, 8,246,752, 8,388,759,
8,702,662, and 8,951,355. International Patents AU 2004235782;
CA 2,565,303. Other US and international patents pending.

1 Karimov, J.H., Gillinov, A.M., Schenck, L., et al. Incidence of chest tube clogging after cardiac surgery:
a single-centre prospective observational study. Eur J Cardiothorac Surg. 2013;44(6):1029-1036.
doi:10.1093/ejcts/ezt140.

US FDA 510(k): K093565; Health Canada License Number 82994;

ARTG Identifier 218317

Manufactured For:

EU Authorized Representative:

ClearFlow, Inc.
1630 S. Sunkist St., Suite E
Anaheim, CA, US, 92806

Emergo Europe
Molenstraat 15
2513 BH, The Hague
The Netherlands

ML004-I
MCV00031391 REVA

2 Shiose, A., Takaseya, T., Fumoto, H., et al. Improved drainage with active chest tube clearance.
Interact CardioVasc Thorac Surg. 2010;10:685-688. doi: 10.1510/icvts.2009.229393.
3 Dixon, B., Santamaria, J.D., Reid, D., et al. The association of blood transfusion with mortality after
cardiac surgery: cause or confounding? Transfusion. 2013;53(1):19-27. doi:
10.1111/j.1537-2995.2012.03697.x.
4 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality
(AHRQ) Healthcare Cost and Utilization Project (HCUP). Data extracted using ICD-9 codes from over
313,000 US adult heart surgery patients. Analysis performed by Fletcher Spaght, Inc.
5 Arakawa, Y., Shiose, A., Takaseya, T. et al. Superior Chest Drainage With an Active Tube Clearance
System: Evaluation of a Downsized Chest Tube. Ann Thorac Surg. 2011;91:580-583. doi:
10.1016/j.athoracsur.2010.10.018.

WITH PLEURAFLOW ACTIVE CLEARANCE TECHNOLOGY